Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
IBD
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - IBD
    TopAbstracts in IBD 05/13/2008 - (DGNews)
    TopAbstracts in IBD 04/29/2008 - (DGNews)
    FDA Approves Certolizumab to Treat Crohn's Disease - (DGNews)
    TopAbstracts in IBD 04/15/2008 - (DGNews)
    Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials - (JAMA)

    News archive

     Recent webcasts/CME - IBD
  • Addressing Treatment Challenges in Ulcerative Colitis: Using Optimum Delivery Systems
  • Azo-Bonded Agents in Ulcerative Colitis: Improving Delivery of 5-ASA
  • Pulmonary Manifestations of Inflammatory Bowel Disease
    Optimizing the Use of Biologics to Achieve Goals of Therapy in IBD

    Webcasts/CME archive

     Recent cases - IBD
      Stroke in Inflammatory Bowel Disease: A Report of Two Cases and Review of the Literature
      Colonic Perforation Following Mild Abdominal Trauma in a Patient with Crohn's Disease: A Case Report
      Takayasu's Arteritis Associated wWith Crohn's Disease: A Case Report
      Granulomatous Cheilitis Associated with Exacerbations of Crohn's Disease: A Case Report
      Pulmonary Manifestations in a Pediatric Patient with Ulcerative Colitis: A Case Report

      Cases archive
        




      my personal edition > ibd > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Tegaserod (Zelnorm) Improves Quality-of-Life Measures Among IBS-With-Constipation Patients

      By Bruce Sylvester

      CHICAGO, IL -- May 20, 2005 -- Tegaserod (Zelnorm(R)), a promotility agent that acts at the serotonin 5-HT4 receptor, significantly improves quality-of-life measures in women with irritable bowel syndrome with a constipation agent (IBS-C), researchers reported here on May 16th at Digestive Disease Week (DDW).

      "The most important finding is that, using this quality-of-life evaluative tool, we identified significant positive effects on quality of life in various domains," said Christopher McBurney, PharmD, clinical researcher, Novartis Pharmaceuticals, Basel, Switzerland.

      "While we already knew that this agent is very effective for IBS with constipation, this new data expands our awareness of its efficacy into other areas related to the disease, which are of great day-to-day concern to IBS-with-constipation patients," Dr. McBurney said.

      United States Food and Drug Administration has already approved tegaserod for short-term management of severe, chronic irritable bowel syndrome in women who have constipation as their main bowel problem.

      To determine the agent's effect on markers of quality of life, the investigators randomized women meeting Rome II criteria for IBS-C to a double-blind, placebo-controlled multicenter study. Women were randomized to tegaserod 6 mg twice daily or placebo. A 2-week baseline period and 2 4-week double-blind periods (phase 1 and phase 2) were separated by a tegaserod-free interval.

      The researchers used the IBS-quality-of-life (IBS-QoL) questionnaire to evaluate the effect of tegaserod therapy on quality of life. Subjects completed the questionnaire at baseline and at the end of phase 1 and 2.

      Dr. McBurney reported the phase 1 results in his presentation. Phase 2 results are being evaluated and will be published at a later date.

      The researchers enrolled 2660 women who were 65 years of age or younger. They randomized 2135 women to tegaserod treatment and 525 to placebo. The mean age was 42 years (range 17-66) and mean duration of IBS symptoms was 13 years. Of these subjects, 1645 tegaserod and 402 placebo patients were evaluable for phase 1 QoL measures.

      Tegaserod subjects reported statistically significant higher overall IBS-QoL scores than placebo subjects (P = .005). The scores were higher in the tegaserod arm in 5 of 8 areas: dysphoria (P = .0008), body image (P = .035), health worry (P = .0006), food avoidance (P = .037), and relationships (P = .0023). The other 3 dimensions (sexual concerns, interference in daily activities, and social reaction) showed trends in favor of tegaserod but were not statistically significant.

      Tegaserod subjects who achieved 50% or higher relief in overall IBS symptoms showed improvements over placebo in all QoL dimensions.

      "This study demonstrates that tegaserod significantly improves QoL in patients with IBS-C," the authors concluded.

      The study was supported by Novartis Pharma AG.


      [Presentation title: Tegaserod Significantly Improves Health-Related Quality Of Life and Patient Satisfaction in Patients With IBS-C. Abstract M994]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send